HC Wainwright Increases Earnings Estimates for Cytosorbents

Cytosorbents Corporation (NASDAQ:CTSO) – Equities research analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for Cytosorbents in a research note issued on Thursday, May 14th. HC Wainwright analyst S. Lee now forecasts that the medical research company will post earnings per share of ($0.04) for the quarter, up from their previous forecast of ($0.05). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cytosorbents’ Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.03 EPS, FY2028 earnings at $0.06 EPS and FY2029 earnings at $0.08 EPS.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The firm had revenue of $8.86 million during the quarter, compared to analysts’ expectations of $9.40 million. Cytosorbents had a negative net margin of 31.85% and a negative return on equity of 235.57%.

Several other research firms also recently weighed in on CTSO. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Thursday, March 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cytosorbents presently has an average rating of “Hold” and an average target price of $5.38.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $0.48 on Tuesday. The company has a market cap of $30.08 million, a PE ratio of -2.52 and a beta of 1.43. The stock’s 50 day simple moving average is $0.63 and its 200-day simple moving average is $0.67. Cytosorbents has a 1-year low of $0.45 and a 1-year high of $1.39. The company has a debt-to-equity ratio of 4.70, a current ratio of 1.09 and a quick ratio of 0.81.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CTSO. Citadel Advisors LLC raised its holdings in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after acquiring an additional 36,790 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Cytosorbents during the 3rd quarter worth $105,000. CIBC Bancorp USA Inc. purchased a new position in shares of Cytosorbents during the 3rd quarter worth $161,000. Finally, CM Management LLC raised its holdings in shares of Cytosorbents by 14.6% during the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after acquiring an additional 188,372 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.